Medical device maker Medtronic plc (NYSE: MDT) on Tuesday reported higher revenues and adjusted earnings for the second quarter of fiscal 2026.
MDT Earnings: Medtronic Q2 FY26 revenue and adj. profit beat estimates
Categories
Health Care
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies
Viatris (VTRS) posts Q3 2025 results and updates 2025 guidance
Pharmaceuticals company Viatris Inc. (NASDAQ: VTRS) on Thursday reported financial results for the third quarter of fiscal 2025, and updated its outlook
Earnings Summary: Humana Q3 2025 profit drops despite higher revenues
Humana Inc. (NYSE: HUM), a leading health and well-being company, on Wednesday reported a decline in adjusted earnings for the third quarter
Key takeaways from Pfizer’s (PFE) Q3 2025 earnings report
Shares of Pfizer Inc. (NYSE: PFE) stayed green during midday trade on Tuesday following the company’s announcement of its third quarter 2025
PFE Earnings: All you need to know about Pfizer’s Q3 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its third quarter 2025 earnings results today. Revenues were $16.7 billion, down 6% on a reported basis
Earnings Summary: Highlights of IDEXX’s Q3 2025 report
Medical device company IDEXX Laboratories, Inc. (NASDAQ: IDXX) on Monday reported higher revenues and earnings for the third quarter of fiscal 2025.
ABBV Earnings: A snapshot of AbbVie’s Q3 2025 report
Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an
BIIB Earnings: A snapshot of Biogen’s Q3 2025 results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported an increase in adjusted profit for the third quarter of 2025 when its revenues remained
Earnings Summary: Cardinal Health Q1 2026 revenue jumps 22%; raises guidance
Pharmaceuticals distributor Cardinal Health (NYSE: CAH) reported a sharp increase in revenue and adjusted earnings for the first quarter of fiscal 2026.
Bristol Myers Squibb (BMY) Earnings: 3Q25 Key Numbers
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2025 earnings results today. Revenues increased 3% year-over-year to $12.2 billion. GAAP net
Eli Lilly (LLY) Earnings: 3Q25 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported its third quarter 2025 earnings results today. Worldwide revenue was $17.60 billion, up 54% from
Key highlights from Merck’s (MRK) Q3 2025 earnings results
Merck & Co., Inc. (NYSE: MRK) reported its third quarter 2025 earnings results today. Total worldwide sales of $17.3 billion were up
UnitedHealth Group’s Q3 2025 earnings fall despite double-digit revenue growth
Healthcare behemoth UnitedHealth Group (NYSE: UNH) announced results for the third quarter of fiscal 2025, reporting an increase in revenues and a
Earnings Summary: HCA Healthcare Q3 adj. profit jumps on strong revenue growth
Health services behemoth HCA Healthcare, Inc. (NYSE: HCA) has reported a sharp increase in adjusted earnings for the third quarter of fiscal
Earnings Summary: A snapshot of Revvity’s (RVTY) Q3 2025 report
Revvity, Inc. (NYSE: RVTY), a provider of health science solutions and technologies, reported a decline in adjusted earnings for the third quarter
Earnings Summary: Highlights of Boston Scientific’s Q3 2025 results
Medical device maker Boston Scientific Corporation (NYSE: BSX) on Wednesday reported financial results for the third quarter of 2025. The company also issued
Intuitive Surgical (ISRG) Q3 FY25 revenue and earnings beat estimates
Medical device company Intuitive Surgical, Inc. (NASDAQ: ISRG) on Wednesday reported stronger-than-expected revenue and earnings for the third quarter of fiscal 2025.
Infographic: How Thermo Fisher (TMO) performed in Q3 2025
Thermo Fisher Scientific Inc. (NYSE: TMO) reported its third quarter 2025 earnings results today. Revenue grew 5% year-over-year to $11.12 billion. Organic
Abbott Laboratories Q3 adj. earnings rise on higher sales; meet Street view
Abbott Laboratories (NYSE: ABT) reported higher sales and adjusted earnings for the third quarter of fiscal 2025. The healthcare company also reaffirmed
Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO
Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies for cancer patients with high unmet medical